Next Article in Journal
Role of the Nuclear Lamina in Age-Associated Nuclear Reorganization and Inflammation
Next Article in Special Issue
Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer
Previous Article in Journal
Mechanical Forces between Mycobacterial Antigen 85 Complex and Fibronectin
Previous Article in Special Issue
Conformational Switching in Bcl-xL: Enabling Non-Canonic Inhibition of Apoptosis Involves Multiple Intermediates and Lipid Interactions

Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies

Clinical Hematology, Nantes University Hospital, 1 place A. Ricordeau, 44000 Nantes, France
CRCINA, INSERM, CNRS, Angers University, Nantes University, 8 quai Moncousu, 44000 Nantes, France
Integrated Cancer Research Center (SIRIC), ILIAD, 5 Allée de l’Ile Gloriette, 44093 Nantes, France
Author to whom correspondence should be addressed.
Cells 2020, 9(3), 717;
Received: 4 February 2020 / Revised: 8 March 2020 / Accepted: 12 March 2020 / Published: 14 March 2020
(This article belongs to the Special Issue Regulation of Apoptosis by the Bcl-2 Family of Proteins)
Apoptosis is a highly conserved mechanism enabling the removal of unwanted cells. Mitochondrial apoptosis is governed by the B-cell lymphoma (BCL-2) family, including anti-apoptotic and pro-apoptotic proteins. Apoptosis evasion by dysregulation of anti-apoptotic BCL-2 members (BCL-2, MCL-1, BCL-XL) is a common hallmark in cancers. To divert this dysregulation into vulnerability, researchers have developed BH3 mimetics, which are small molecules that restore effective apoptosis in neoplastic cells by interfering with anti-apoptotic proteins. Among them, venetoclax is a potent and selective BCL-2 inhibitor, which has demonstrated the strongest clinical activity in mature B-cell malignancies, including chronic lymphoid leukemia, mantle-cell lymphoma, and multiple myeloma. Nevertheless, mechanisms of primary and acquired resistance have been recently described and several features such as cytogenetic abnormalities, BCL-2 family expression, and ex vivo drug testing have to be considered for predicting sensitivity to BH3 mimetics and helping in the identification of patients able to respond. The medical need to overcome resistance to BH3 mimetics supports the evaluation of innovative combination strategies. Novel agents including MCL-1 targeting BH3 mimetics are currently evaluated and may represent new therapeutic options in the field. The present review summarizes the current knowledge regarding venetoclax and other BH3 mimetics for the treatment of mature B-cell malignancies. View Full-Text
Keywords: venetoclax; BH3 mimetics; BCL-2; MCL-1; apoptosis; myeloma; lymphoma; leukemia venetoclax; BH3 mimetics; BCL-2; MCL-1; apoptosis; myeloma; lymphoma; leukemia
Show Figures

Figure 1

MDPI and ACS Style

Jullien, M.; Gomez-Bougie, P.; Chiron, D.; Touzeau, C. Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies. Cells 2020, 9, 717.

AMA Style

Jullien M, Gomez-Bougie P, Chiron D, Touzeau C. Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies. Cells. 2020; 9(3):717.

Chicago/Turabian Style

Jullien, Maxime, Patricia Gomez-Bougie, David Chiron, and Cyrille Touzeau. 2020. "Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies" Cells 9, no. 3: 717.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop